[go: up one dir, main page]

WO2010023512A8 - Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them - Google Patents

Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2010023512A8
WO2010023512A8 PCT/IB2009/000097 IB2009000097W WO2010023512A8 WO 2010023512 A8 WO2010023512 A8 WO 2010023512A8 IB 2009000097 W IB2009000097 W IB 2009000097W WO 2010023512 A8 WO2010023512 A8 WO 2010023512A8
Authority
WO
WIPO (PCT)
Prior art keywords
pain
vanilloid receptor
receptor modulators
preparation
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/000097
Other languages
French (fr)
Other versions
WO2010023512A1 (en
Inventor
Balasubramanian Gopalan
Pal Manojit
Kodimuthali Arumugam
Dhingra Nidhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Matrix Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd filed Critical Matrix Laboratories Ltd
Publication of WO2010023512A1 publication Critical patent/WO2010023512A1/en
Publication of WO2010023512A8 publication Critical patent/WO2010023512A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention pertains to novel vanilloid receptor modulators of general formula I, process for their preparation, and pharmaceutical compositions containing them. These novel vanilloid receptor modulators are valuable agents for preventing, ameliorating, or treating vanilloid receptor mediated diseases and are useful, e.g., for the treatment of acute pain, chronic pain, nociceptive pain, neuropathic pain, post¬ operative pain, dental pain, cancer pain, or pain due to retinopathy, stroke, urinary incontinence, inflammatory bowel disease, irritation of skin, dermatitis and muscle spasms. (I) General Formula(I)
PCT/IB2009/000097 2008-08-28 2009-01-15 Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them Ceased WO2010023512A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2091CH2008 2008-08-28
IN2091/CHE/2008 2008-08-28

Publications (2)

Publication Number Publication Date
WO2010023512A1 WO2010023512A1 (en) 2010-03-04
WO2010023512A8 true WO2010023512A8 (en) 2010-08-05

Family

ID=40457335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/000097 Ceased WO2010023512A1 (en) 2008-08-28 2009-01-15 Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them

Country Status (1)

Country Link
WO (1) WO2010023512A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104569222A (en) * 2015-01-29 2015-04-29 深圳爱湾医学技术服务有限公司 Urine treatment method
AU2019207887B2 (en) * 2018-01-11 2024-05-23 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
JOP20210217A1 (en) 2019-02-15 2023-01-30 Novartis Ag Methods for treating ocular surface pain
JP6994061B2 (en) 2019-02-15 2022-01-14 ノバルティス アーゲー Preparation of 4- (7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3-yl) -benzonitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316972B2 (en) * 2004-11-24 2011-11-10 Abbvie Inc. Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
JP2008534593A (en) * 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds, and methods of use thereof
US7842703B2 (en) * 2005-10-07 2010-11-30 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
WO2008059339A2 (en) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
CN101563318A (en) * 2006-12-20 2009-10-21 艾博特公司 N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain

Also Published As

Publication number Publication date
WO2010023512A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
PH12012500646A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
EA200802020A1 (en) TETRAHYDROPYRIMIDAOZEPINA AND THEIR APPLICATION AS TRPV 1 MODULATORS
CL2009000135A1 (en) Compounds derived from substituted 1,4-benzodiazepines, dipeptidylpeptidase inhibitors iv (dpp-iv); pharmaceutical composition; preparation procedure; and its use in the treatment of diseases such as type 2 diabetes, cataracts, glaucoma, benign prostatic hypertrophy, cancer, among others; intermediate compounds.
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
MX373783B (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA201071045A1 (en) COMPOUNDS OF OXADIAZOANTHRACENE FOR THE TREATMENT OF DIABETES
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
CL2007002272A1 (en) COMPOUNDS DERIVED FROM N-METHYL-C-NORMORFINAN; PHARMACEUTICAL COMPOSITION; AND USE FOR THE REDUCTION OF SECONDARY EFFECTS OF THE TREATMENT OF OPIOIDES SUCH AS CONSTIPATION AND NAUSEAS, AND TO TREAT DISORDERS MEDIATED BY THE ACTIVITY OF RECEPTORS OR
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
IN2014MN00139A (en)
EA200970065A1 (en) DERIVATIVES OF PIPERAZINIL, INTENDED FOR THE TREATMENT OF DISEASES MEDIATED BY GPR38
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
MX2012002481A (en) Therapeutic aryl-am i do-aryl compounds and their use.
MX2011012669A (en) Novel glucocorticoid receptor agonists.
TW200611695A (en) Pyrrolopyridine derivatives
WO2010129048A3 (en) Therapeutic compounds
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP4357334A3 (en) Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2010023512A8 (en) Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09785786

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09785786

Country of ref document: EP

Kind code of ref document: A1